Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgments

A.S.a., A.S.h., M.A., S.H., and O.A.O. conducted the clinical trial and data collection. P.S., G.B., and M.A. performed the statistical analysis. A.S.a., H.M., and O.A.O. analyzed the data and wrote the paper. All authors edited and contributed to the manuscript writing.

Disclosure statement

1. Ahmed Sawas – consultancy from Seattle Genetics, Gilead, Daiichi Sanko; Research funding from Affimed.

2. Helen Ma – nothing to report.

3. Andrei Shustov –travel support and research funding from Spectrum Pharmaceuticals; Consultancy from Kyowa-Hakko-Kirin and Portola.

4. Pamela Hsu – employee of Spectrum Pharmaceuticals.

5. Gajanan Bhat – employee of Spectrum Pharmaceuticals.

6. Mark Acosta – employee of Acrotech BioPharma.

7. Steven Horwitz – research support from Aileron Therapeutics, Kyowa Hakko Kirin Pharma, Celgene, Takeda/Millennium, Verastem, Seattle Genetics, ADCT Therapeutics, Forty-Seven Inc., Trillium; Consulting from Affimed, Kyowa Hakko Kirin Pharma, Celgene, Portola Pharmaceuticals, Takeda/Millennium, Verastem, Miragen Therapeutics Inc, Seattle Genetics, and ADCT Therapeutics.

8. Owen A. O’Connor – consultancy from Celgene and Mundipharma. Research funding from ADCT Therapeutics, Affimed, Agensys, Celgene, Merck, Seattle Genetics, Spectrum, TG Therapeutics, Trillium Pharmaceuticals, and Verastem. Scientific advisory role for Celgene (Data Safety Monitoring Committee), Mundipharma, and TG Therapeutics (travel support only).

Data availability

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.